Shooting for $100M IPO, Schrödinger takes the wraps off its five internal drugs and discloses deal details
Just before last year’s JP Morgan confab kicked off, Schrödinger unveiled its first venture round featuring institutional investors before later closing the Series E at …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.